Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrons01:10

Nephrons

2.2K
The kidneys are intricate organs with millions of working units known as nephrons. Each nephron features two major structures: the renal corpuscle, which facilitates blood plasma filtration, and the renal tubule, which handles the glomerular filtrate. Blood supply is directly linked to the nephrons. The renal corpuscle consists of the glomerulus, a capillary network, and the Bowman's capsule, a double-walled epithelial structure that encases the glomerulus. The filtering of blood plasma...
2.2K
Renal Corpuscle01:20

Renal Corpuscle

1.7K
The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extranodal natural killer/T-cell lymphoma: From fatal to curable.

CA: a cancer journal for clinicians·2026
Same author

Factor X colocalizes with amyloid light chain deposits in AL amyloidosis: evidence from three patients.

Haematologica·2026
Same author

Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.

Blood·2026
Same author

Health-related quality of life and mental health in autoimmune thrombotic thrombocytopenic purpura patients in the caplacizumab era.

Research and practice in thrombosis and haemostasis·2026
Same author

Clinicopathological Spectrum and Treatment Outcomes of Cryofibrinogen-Associated Nephropathies.

Kidney international reports·2026
Same author

Ethnicity affects relapse-free survival in immunemediated thrombotic thrombocytopenic purpura.

Haematologica·2026

Related Experiment Video

Updated: Jun 5, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K

Kidney disease in multiple myeloma.

Frank Bridoux1, Nelson Leung2, Samih H Nasr3

  • 1Department of Nephrology, Centre de référence maladies rares «Amylose AL et autres maladies par dépôts d'immunoglobulines monoclonales», Centre Hospitalier Universitaire de Poitiers, Université de Poitiers, Poitiers, France.

Presse Medicale (Paris, France : 1983)
|December 11, 2024
PubMed
Summary

Multiple myeloma often causes kidney disease, primarily light chain cast nephropathy (LCCN). Prompt treatment focusing on reducing monoclonal free light chains (FLC) is crucial for kidney recovery and survival.

Keywords:
Acute kidney injuryFree light chainsHemodialysisLight chain cast nephropathyMultiple myeloma

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.0K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K

Related Experiment Videos

Last Updated: Jun 5, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.0K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K

Area of Science:

  • Nephrology
  • Hematology
  • Oncology

Background:

  • Renal disease is a common, serious complication of symptomatic multiple myeloma.
  • Light chain cast nephropathy (LCCN), caused by monoclonal free light chain (FLC) precipitation, is the most frequent myeloma-related kidney lesion.
  • LCCN significantly increases morbidity, reduces quality of life, and lowers overall survival.

Purpose of the Study:

  • To highlight the importance of rapid identification and management of myeloma-related kidney disease, particularly LCCN.
  • To outline current and potential therapeutic strategies for LCCN.
  • To emphasize the role of serum FLC level monitoring in assessing treatment efficacy and predicting renal recovery.

Main Methods:

  • Review of current literature and clinical practices for managing multiple myeloma with renal complications.
  • Analysis of diagnostic criteria for LCCN, including serum FLC levels and proteinuria.
  • Discussion of therapeutic approaches, including fluid expansion, correction of precipitating factors, anti-myeloma therapies, and adjunctive treatments like plasma exchange or high-cutoff hemodialysis.

Main Results:

  • LCCN typically presents with severe acute kidney injury, high serum FLC levels (>500 mg/l), and predominant light chain proteinuria (<10% urine albumin/creatinine ratio).
  • Early and substantial reduction in serum FLC levels is critical for renal recovery.
  • Standard treatment for newly diagnosed patients often involves bortezomib, high-dose dexamethasone, and an anti-CD38 monoclonal antibody.

Conclusions:

  • Urgent, multi-faceted treatment is required for LCCN, including supportive care and effective anti-myeloma therapy tailored to renal function and patient frailty.
  • Histological assessment can aid in prognosis and treatment refinement.
  • Renal transplantation is a viable option for selected patients with end-stage kidney disease due to improved survival rates.